Companies: 49,246 Total Market Cap: 132583394431625.88

CureVac N.V.

NASDAQ: CVAC
Healthcare Biotechnology
Rank #9517
Market Cap 963.67 M
Volume 1.60 M
Price 4.28
Change (%) 10.59%
Country or region Germany Germany

CureVac N.V.'s latest marketcap:

963.67 M

As of 05/20/2025, CureVac N.V.'s market capitalization has reached $963.67 M. According to our data, CureVac N.V. is the 9517th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 963.67 M
Revenue (ttm) 554.07 M
Net Income (ttm) 167.91 M
Shares Out 225.16 M
EPS (ttm) 0.75
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/20/2025
Market Cap Chart
Data Updated: 05/20/2025

CureVac N.V.'s yearly market capitalization.

CureVac N.V. has seen its market value drop from $14.31 B to $963.67 M since 2020, representing a total decrease of 93.26% and an annual compound decline rate (CAGR) of 45.94%.
Date Market Cap Change (%)
05/20/2025 $963.67 M 2.14%
12/31/2024 $764.91 M -18.86%
12/29/2023 $942.72 M -17.82%
12/30/2022 $1.15 B -82.12%
12/31/2021 $6.42 B -55.14%
12/31/2020 $14.31 B

Company Profile

About CureVac N.V.

CureVac N.V. is a pioneering biopharmaceutical company specializing in transformative medicines based on messenger ribonucleic acid (mRNA) technology. Headquartered in Tübingen, Germany, and founded in 2000, the company leverages its expertise to develop innovative therapies across multiple disease areas.

Core Focus Areas

  • Prophylactic Vaccines: Targeting infectious diseases, including urinary tract infections (UPEC bacteria) and SARS-CoV-2 variants.
  • Oncology: Developing off-the-shelf and personalized cancer immunotherapies.
  • Molecular Therapy: Optimizing mRNA to stimulate therapeutic protein production in human cells.

Key Technologies & Products

  • The RNA Printer: A fully automated, compact system for mRNA vaccine and therapeutic manufacturing.
  • Clinical Candidates: Includes CV0601 and CV0701 (Phase 2 for SARS-CoV-2), CVGBM (for glioblastoma), and precision immunotherapies for non-small cell lung cancer.
  • mRNA Delivery: Enables targeted protein production in cells, enhancing therapeutic efficacy.

CureVac continues to advance its pipeline, focusing on cutting-edge mRNA solutions to address unmet medical needs in vaccines, oncology, and beyond.

Frequently Asked Questions

As of 05/20/2025, CureVac N.V. (including the parent company, if applicable) has an estimated market capitalization of $963.67 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

CureVac N.V. global market capitalization ranking is approximately 9517 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Germany
Founded 2000
IPO Date 08/14/2020
Employees 983
CEO Alexander Zehnder
Sector Healthcare
Industry Biotechnology
Address Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany
Website https://www.curevac.com
People Also Watch
VRTX
447.18 10.59%
CSL Limited
156.67 10.59%
REGN
614.79 10.59%
KRX-207940
732.25 10.59%